zilganersen (ION373) / Ionis - LARVOL DELTA

Case Study: EEG-Guided Sedation in a Pediatric Patient with Alexander's Disease (IARS-SOCCA 2025) - "The patient was enrolled in a clinical trial studying the efficacy of intrathecal ION373, an antisense oligonucleotide-based therapy administered via intrathecal infusion under general anesthesia that inhibits the amount of GFAP protein produced...In past procedures, the patient was induced with sevoflurane and maintained on a regimen of propofol ranging from 100 mcg/kg/min to 200 mcg/kg/min...In this report we show how EEG was used to guide anesthetic care for a pediatric patient with Alexander's Disease, reducing the amount of propofol used by 50% and leading to notably shorter wash-off time and time to emergence from anesthesia.We believe that this patient's increased sensitivity to propofol measured through the EEG could be explained by the effects of Alexander's Disease on astrocyte metabolism. Astrocytes play a key role in the regulation of neuronal metabolism.5 Past work has shown that anesthetic drugs impair neuronal mitochondrial function, shifting..."

Case study • Clinical • Anesthesia • CNS Disorders • Developmental Disorders • Epilepsy • Hypotension • Pediatrics • Solid Tumor • GFAP

Zilganersen granted U.S. FDA Fast Track designation for people living with Alexander disease (PRNewswire) - "Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that the U.S. Food and Drug Administration (FDA) has granted zilganersen Fast Track designation for the treatment of children and adults with an ultra-rare, progressive and ultimately fatal neurological disorder known as Alexander disease (AxD). Topline data from the pivotal study of zilganersen is expected in the second half of 2025. The FDA grants investigational medicines Fast Track designation to facilitate the development and expedite the review of medicines that demonstrate the potential to treat serious conditions and fill an unmet medical need."

Fast track • P3 data: top line • Genetic Disorders

A Study to Evaluate the Safety and Efficacy of Zilganersen (ION373) in Patients With Alexander Disease (AxD) (clinicaltrials.gov) - P3 | N=73 | Enrolling by invitation | Sponsor: Ionis Pharmaceuticals, Inc. | Recruiting ➔ Enrolling by invitation | Trial completion date: Mar 2029 ➔ Sep 2029 | Trial primary completion date: Mar 2025 ➔ Sep 2025

Enrollment status • Trial completion date • Trial primary completion date • CNS Disorders • Rare Diseases • FAP • GFAP

A Study to Evaluate the Safety and Efficacy of ION373 in Patients With Alexander Disease (AxD) (clinicaltrials.gov) - P3 | N=73 | Recruiting | Sponsor: Ionis Pharmaceuticals, Inc. | Trial completion date: Nov 2025 ➔ Mar 2029 | Trial primary completion date: Feb 2024 ➔ Mar 2025

Trial completion date • Trial primary completion date • CNS Disorders • Rare Diseases • GFAP

"We also entered our late-stage pipeline with the initiation of pivotal studies for ION363 in patients with FUS-#ALS. And the ION373 in patients with #Alexandersdisease. #raredisease #neurotwitter #MedTwitter #neurolgy #ALSAwarenessMonth $ions $biib" (@IonisDisrupts)

Clinical • Amyotrophic Lateral Sclerosis • Rare Diseases

A Study to Evaluate the Safety and Efficacy of ION373 in Patients With Alexander Disease (AxD) (clinicaltrials.gov) - P3; N=58; Recruiting; Sponsor: Ionis Pharmaceuticals, Inc.; Not yet recruiting ➔ Recruiting

Enrollment open • GFAP